CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...